Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors

Journal of Immunology

Volumn 165, Issue 7, 2000, Pages 3656-3662

  Plautz, G E ^a   Mukai, S ^a   Cohen, P A ^a   Shu, S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CHIMERA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FIBROSARCOMA; IMMUNE RESPONSE; INTRACRANIAL TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; TUMOR GROWTH; TUMOR REGRESSION;

EID: 0034292408     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.7.3656     Document Type: Article

References (56)

1. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice
2. + T cells
3. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts
4. 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy
5. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression
6. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
7. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
8. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: Association with disease progression
9. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice
10. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and LL-2
11. Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules
12. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells
13. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells
14. Treatment of marine gliomas by adoptive transfer of ex-vivo activated tumor-draining lymph node cells
15. Treatment of subcutaneous tumor with adoptively transferred T cells
16. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression
17. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy
18. - helper cells that secrete interleukin 2 (IL-2), II,-3, IL-4, and interferon γ
19. Regulation of adhesion molecule expression by CD8 T cells in vivo
20. Antigen-specific development of primary and memory T cells in vivo
21. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes
22. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes
23. Treatment of murine primary tumors with systemic interleukin-2 and tumor infiltrating lymphocytes
24. Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors
25. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
26. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
27. Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells
28. Identification of unique tumor-specific antigens as a novel Class I major histocompatibility molecule
29. Molecular characterization of novel H-2 class I molecules expressed by a C3H UV-induced fibrosarcoma
30. Tumor immunity in perforin-deficient mice: A role for CD95 (Fas/APO-1)
31. Molecular mechanisms of immune-mediated lysis of murine renal cancer: Differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells
32. + T cells in IL-12-induced immune responses in vivo
33. Killing mechanisms of cytotoxic lymphocytes
34. Decreased tumor surveillance in perforin-deficient mice
35. Cross-priming for a secondary cytotoxic response to min6r H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay
36. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming
37. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
38. In a radiation chimaera, host H-2 antigens determine immune responsiveness of donor cytotoxic cells
39. In irradiation chimeras, K or D regions of the chimeric host, not of the donor lymphocytes, determine immune responsiveness of antiviral cytotoxic T cells
40. On the thymus in the differentiation of "H-2 self-recognition" by T cells: Evidence for dual recognition?
41. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
42. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-beating mice
43. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules
44. Reciprocal control of T helper cell and dendritic cell differentiation
45. + T cells similar to those found in mice with anterior chamber-associated immune deviation
46. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose
47. + T-cell tolerance by cross-presentation of self antigens
48. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction
49. + T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity
50. Requirements for T cell recognition and elimination of retrovirally-transformed cells
51. - T cells: Tumor eradication does not require participation of cytotoxic T cells
52. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
53. Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cells
54. + T cells in the antitumor immune response
55. + T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection
56. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines